Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT02512302 is registered in ClinicalTrials.gov with Sunovion Respiratory Development Inc. as lead sponsor.

NCT NCT02512302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02512302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Sunovion Respiratory Development Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
April 30, 2016
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

copd